A rare case of alveolar hemorrhage with hypertensive emergency

Sho Hamaguchi, MDa, Hitoshi Suzuki, MD, PhD*, Maki Hamaguchi, MDa, Masako Iwasaki, MDa, Hiromitsu Fukuda, MD, PhDb, Hisatsugu Takahara, MD, PhDb, Shigeki Tomita, MD, PhDb, Yusuke Suzuki, MD, PhDb

Abstract

Introduction: Alveolar hemorrhage presents with severe respiratory failure, requiring prompt diagnosis and treatment. Alveolar hemorrhage is often caused by autoimmune diseases accompanied by progressive renal dysfunction. However, few cases without autoimmune diseases occur, making diagnosis difficult. Here, we report a case of alveolar hemorrhage with hypertensive emergency.

Patient concerns: A 28-year-old man presented with dyspnea and bloody sputum. His blood pressure was 200/120 mm Hg.

Diagnosis: The chest computed tomography showed suggestive of alveolar hemorrhage. Renal dysfunction and proteinuria were observed. However, autoantibodies were not detected. Echocardiogram revealed left ventricular function decrease. Ejection fraction was 20% to 30% with no ventricular asynergy or any valvular diseases. Brain magnetic resonance imaging showed hyperintense lesions on fluid-attenuated inversion recovery in the white matter of both cerebral and right cerebellar hemispheres, which were compatible with posterior reversible encephalopathy syndrome. Renal biopsy did not reveal any immune-mediated glomerulonephritis or vasculitis, but hypertensive nephropathy was diagnosed.

Interventions: Blood pressure was controlled with combination therapy using calcium channel blocker, angiotensin II receptor blocker, α1 blocker, and β blocker.

Outcomes: Alveolar hemorrhage and proteinuria improved with strict blood pressure control.

Conclusion: This case indicates that severe hypertension can possibly cause alveolar hemorrhage. Accumulating these cases is important for general physicians to diagnose the alveolar hemorrhage with hypertensive emergency in its early stage and to avoid unnecessary treatment such as immunosuppressive therapy.

Abbreviation: ARB = angiotensin II receptor blocker.

Keywords: alveolar hemorrhage, autoimmune diseases, hypertension, renal biopsy, vasculitis

1. Introduction

Malignant hypertension is a clinical syndrome characterized by marked blood pressure elevation with widespread acute arteriolar injuries.[1] These vascular damages, namely proliferative endarteritis of small arteries and fibrinoid necrosis of arterioles, are observed in a variety of organs.[1] As a result, the stenosis of vascular lumen causes ischemia, necrosis, and hemorrhage of various tissues. Although hemorrhage of the retina, central nervous system, and kidney are reported in malignant hypertension, alveolar hemorrhage is not common.[1]

Alveolar hemorrhage is a clinical syndrome in which alveolar capillaries are damaged due to various causes, with symptoms of bloody sputum, cough, fever, and progressive anemia. The causes of alveolar hemorrhage are generally autoimmune diseases, such as vasculitis, and drug-induced hemorrhage.[2] However, alveolar hemorrhage and progressive renal dysfunction can sometimes occur without obvious autoantibody detection or drug use history, which is often difficult to distinguish from antineutrophil cytoplasmic antibody-associated vasculitis and anti-GBM syndrome.[3] Here, we report a rare case of alveolar hemorrhage accompanied by severe hypertension without any autoimmune diseases.
2. Case presentation

A 28-year-old man was diagnosed with hypertension after a medical examination 3 years ago; however, secondary hypertension was not diagnosed. He started treatment with antihypertensive drugs, but he defaulted on taking his medication. He has a history of funnel chest and asthma during childhood and had no specific family history of any illness. He complained of dyspnea and bloody sputum, for which he consulted a primary physician. He visited our hospital due to abnormal shadows in the right lung field and renal dysfunction. His blood pressure was 200/120 mm Hg, and he showed sinus tachycardia (125 beats/min). His percutaneous oxygen saturation level was 95% in room air, sitting breathing was observed, and crackles were heard in the right lung field. Abdominal vascular murmur was not heard. Laboratory data was as follows: white blood cell count 3800/μL; hemoglobin, 9.9 g/dL; platelet count, 188 × 10^3/μL; lactate dehydrogenase, 869 IU/L; and C-reactive protein, 37.1 mg/dL. Urinalysis showed proteinuria but no microscopic hematuria. The total protein to creatinine ratio in spot urine was 3.1 g/gCr. The plasma renin activity was 14 ng/mL/h and plasma aldosterone concentration was 1190 pg/mL. The plasma noradrenaline concentration was 870 pg/mL, however, level of urinary metanephrines excretion was within the normal range and the computed tomography detected no obvious tumor. The levels of thyroid-stimulating hormone and free thyroxine were within the normal range (Table 1). An electrocardiogram showed sinus rhythm at a rate of 125 beats/min. An echocardiogram revealed a decrease in left ventricular function with an ejection fraction of 20% to 30% and no ventricular asynergy or any valvular diseases. Fundoscopic examination showed redness and edema of the bilateral optic discs, which was Keith-Wagener grade IV. Chest X-ray showed right lung field infiltration (Fig. 1A) and chest computed tomography detected diffuse bilateral infiltration shadows suggestive of alveolar hemorrhage (Fig. 1B). Brain magnetic resonance imaging indicated hypointense lesions on fluid-attenuated inversion recovery in the white matter of both cerebral and right cerebellar hemispheres, which were compatible with posterior reversible encephalopathy syndrome (Fig. 2A). An acute cerebral infarction was also observed in the right cerebellar hemisphere (Fig. 2B). Blood pressure was controlled to 130/90 mm Hg with combination therapy using several antihypertensive drugs, such as calcium channel blocker, angiotensin II receptor blocker (ARB), α1 blocker and β blocker. The dyspnea gradually improved, and chest X-ray revealed improvement of the alveolar hemorrhage. The dyspnea and right lung field infiltration shadows completely disappeared on day 10. Proteinuria and renal dysfunction also improved compared to those at admission, but the renal dysfunction persisted (estimated glomerular filtration rate 16 mL/min/1.73 m^2). Renal biopsy was performed on day 18 of the definitive diagnosis of renal dysfunction. Light microscopic examination showed glomerular collapse (Fig. 3A) and thrombus-like lesion in a glomerulus, which is typical for thrombotic microangiopathy (Fig. 3B). Subendothelial edema was observed in a part of the glomerular capillary walls (Fig. 3C). Additionally, marked intimal thickening with concentric fibrosis was observed in the blood vessels (Fig. 3D). There was no significant finding in the immunofluorescence analysis (Fig. 3E). Electron microscopic examination showed thickening and meandering of glomerular basement membrane, and subendothelial edema was also observed (Fig. 3F). However, no electron-dense deposits were detected. Based on the above findings, hypertensive nephropathy was diagnosed due to hemodynamic changes. Thus, ARB was used not only for blood pressure control but also for protection of renal function.

He was discharged on day 24 with strict blood pressure control around 120/80 mm Hg. Renal dysfunction remained, however, no further deterioration was observed during 6 months of observation periods after discharge.

### Table 1

**Clinical examination at the admission.**

| Hematological |  |
|---------------|---|
| WBC           | 3800 g/μL |
| Hb            | 9.9 g/dL |
| Plt           | 18.8 x10^3/μL |

| Coagulation test |  |
|------------------|---|
| PT-INR           | 1.32 |
| APTT             | 43.1 seconds |
| D-dimer          | 2.6 μg/mL |
| SF               | 17.5 μg/mL |

| Urinalysis      |  |
|-----------------|---|
| Protein         | 3.1 g/gCr |
| RBC             | 5-9 HPF |
| WBC             | 1-4 HFP |
| U-NAG           | 58.8 IU/L |
| U-β2MG          | 1460 μg/L |
| Metanephrines   | 0.11 mg/day |

**Blood biochemistry**

| Parameter      | Value     |
|----------------|-----------|
| TP             | 5.7 g/dL  |
| Alb            | 2.7 g/dL  |
| BUN            | 42 mg/dL  |
| Cre            | 3.2 mg/dL |
| eGFR           | 21 mL/min/1.73m^2 |
| UA             | 8.5 mg/dL |
| Na             | 133 mEq/L |
| K              | 3.6 mEq/L |
| Cl             | 94 mEq/L  |
| Ca             | 8.5 mg/dL |
| AST            | 42 IU/L   |
| ALT            | 27 IU/L   |
| LDH            | 869 IU/L  |
| ALP            | 489 IU/L  |
| γ-GTP          | 155 IU/L  |
| T-Bil          | 1.7 IU/L  |
| CK             | 155 IU/L  |
| CRP            | 37.1 mg/dL|
| BNP            | 566.8 pg/mL|
| TSH            | 2.2 μIU/mL|
| FT3            | 1.99 pg/mL|
| FT4            | 1.7 ng/dL |
| Aldosterone    | 1190 pg/mL|
| Plasma renin activity | 14 ng/mL/hr |
| Cortisol       | 3.98 μg/dL|
| Adrenalin      | 20 pg/mL  |
| Noradrenalin   | 870 pg/mL |
| Dopamine       | 25 pg/mL  |

**Blood gas analysis**

| Parameter | Value |
|-----------|-------|
| pH        | 7.437 |
| PCO₂      | 34 mm Hg |
| PO₂       | 76.3 mm Hg |
| HCO₃⁻     | 24.4 mmol/L |
| Lac       | 13.8 mg/dL |
| BE        | 1.2 mmol/L |

| Immunological test | Value |
|--------------------|------|
| RF                 | <10 IU/mL |
3. Discussion

Failure to diagnose and treat alveolar hemorrhage in its early stage may lead to acute respiratory failure and death. The overall mortality rate is reported to be 37%. The causes of alveolar hemorrhage are divided into immunological abnormalities, such as vasculitis, antiglomerular basement membrane antibody disease, connective tissue disease, and nonimmunological abnormalities, such as infection and cancer. Moreover, alveolar hemorrhage may be induced by severe hypertension and is commonly accompanied by renal dysfunction; it is often difficult to differentiate from the immunological abnormalities.

In the previously reported 7 cases with alveolar hemorrhage induced by severe hypertension and the present case, all the patients were men with renal dysfunction. Furthermore, most cases had a history of hypertension on a yearly basis and multiple organ disorders, such as hypertensive retinopathy and heart failure (Table 2). Because strict control of blood pressure improved alveolar hemorrhage, these cases suggest that extremely severe hypertension can lead to hemorrhage. The mechanism of how high blood pressure can cause alveolar bleeding remains unclear, but humoral factors might be involved in the alveolar capillaries. The damaged endothelium increases permeability and activates the coagulation cascade, including platelet activation and fibrin deposition. Red blood cells are destroyed within vessels, resulting in end-organ ischemia.

Hida et al. reported that alveolar capillaries might be injured as the capillaries in systemic circulation are injured by malignant

| Table 1 (Continued) |
|--------------------|
| **ANA** | <×40 |
| **PR3-ANCA** | <1.0 U/mL |
| **MPO-ANCA** | <1.0 U/mL |
| **Anti-GBM-Ab** | <2.0 U/mL |
| **CH50** | 62 U/mL |
| **C3** | 127 mg/mL |
| **C4** | 38 mg/mL |
| **IgG** | 624 mg/dL |
| **IgA** | 243 mg/dL |
| **IgM** | 100 mg/dL |

| Figure 1. (A) Chest X-ray showing right lung field infiltration. (B) Chest computed tomography showing diffuse bilateral infiltration shadows. |
| Figure 2. (A) Brain magnetic resonance imaging showing hyperintense lesions on fluid-attenuated inversion recovery in the white matter of both cerebral and right cerebellar hemispheres. (B) Hyperintense lesion on diffusion imaging in the right cerebellar hemisphere. |
hypertension, resulting in alveolar hemorrhage. Meanwhile, other reports suggested that left ventricular dysfunction resulting from systemic hypertension can cause pulmonary edema, leading to hemorrhage.\cite{7,8} There are other hypotheses stating that smoking, platelet dysfunction, and air travel are associated with alveolar bleeding.\cite{7,9}

In this case, there were no other bleeding lesions in the vasculature of the systemic circulation, and uncontrolled long-term hypertension resulted in severely impaired cardiac function. Thus, the cause of alveolar hemorrhage may not be alveolar capillary injury, but pulmonary edema caused by left ventricular dysfunction. Pulmonary circulation is somewhat free of systemic hypertension because it is separated from the systemic circulation by the heart; however, it can be affected by systemic hypertension with left ventricular dysfunction.\cite{10}

4. Conclusion

In summary, the causes of alveolar hemorrhage are generally known to be autoimmune diseases, such as vasculitis. In the present case, no autoimmune diseases were detected, and strict control of blood pressure improved alveolar hemorrhage, suggesting severe hypertension may cause alveolar hemorrhage, which is rarely reported and considered to be a valuable case. Surgical lung biopsy is required to make a defined diagnosis of

Table 2

| Cases | Age | Gender | History of hypertension | Blood pressure (mm Hg) | Serum creatinine level (mg/dL) | Complication |
|-------|-----|--------|-------------------------|------------------------|-------------------------------|--------------|
| 1     | 34  | Male   | None                    | 220/135                | 4.9                           |              |
| 2     | 26  | Male   | 3 yr                    | 210/150                | 2.2                           |              |
| 3     | 38  | Male   | 3 mo                    | 220/120                | 3.2                           | Retinopathy, cerebral infarction |
| 4     | 32  | Male   | 5 yr                    | 290/150                | 8.2                           | Retinopathy, heart failure |
| 5     | 27  | Male   | Several years           | 180/100                | 5.2                           | Retinopathy |
| 6     | 27  | Male   | 2 yr                    | 200/128                | 4.4                           | Retinopathy, heart failure |
| 7     | 51  | Male   | None                    | 220/130                | 8.0                           |              |
| Present case | 28 | Male   | 3 yr                    | 220/120                | 3.2                           | Retinopathy, heart failure |

Figure 3. (A and B) Light microscopic examination showing glomerular collapse and thrombus-like lesion in a glomerulus (arrow) (A: periodic acid methenamine silver stain, ×100 B: periodic acid methenamine silver stain, ×200). (C) Subendothelial edema observed in a part of the glomerular capillary walls (arrow) (periodic acid methenamine silver stain, ×300). (D) Marked intimal thickening with concentric fibrosis observed in the blood vessels (periodic acid methenamine silver stain, ×200). (E) No significant finding in the immunofluorescence analysis. (F) Electron microscopic examination showing thickening and meandering of glomerular basement membrane, and subendothelial edema observed (arrow). No electron-dense deposits were observed.
alveolar hemorrhage of unknown cause; however, it is highly invasive and often cannot be performed. Accumulating these cases may aid general physicians in diagnosing this rare condition in its early stage and avoiding unnecessary treatment, such as immunosuppressive therapy.

Acknowledgments
This study was supported in part by a Grant-in-Aid for Intractable Renal Diseases Research, Research on rare and intractable disease, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (Grant Number:20FC1045).

Author contributions
Conceptualization: Hitoshi Suzuki
Data curation: Sho Hamaguchi, Maki Hamaguchi, Masako Iwasaki
Formal analysis: Hitoshi Suzuki, Shigeki Tomita
Funding acquisition: Hitoshi Suzuki, Yusuke Suzuki
Methodology: Hiromitsu Fukuda, Hisatsugu Takahara
Supervision: Yusuke Suzuki
Writing—original draft: Sho Hamaguchi
Writing—review & editing: Hitoshi Suzuki, Yusuke Suzuki
All authors have read and approved the manuscript

References
[1] Nolan CR, Linas SL. Malignant hypertension and other hypertensive crisis. in: Diseases of the Kidney, vol II. Schrier RW, Gottschalk CW eds. New York, NY, Little Brown; 1996:1475–1534.
[2] de Prost N, Parrot A, Picard C, et al. Diffuse alveolar haemorrhage: factors associated with in-hospital and long-term mortality. Eur Respir J. 2010;35:1303–11.
[3] Suzuki A, Nakagawa N, Maruyama K, et al. Diffuse alveolar hemorrhaging with hypertensive emergency: a rare but important cause of hemoptysis. Intern Med. 2019;58:1511–6.
[4] Duarte JC, Leal R, Escada L, et al. Systemic hypertension and the pathogenesis of diffuse alveolar haemorrhage. Rev Port Pneumol (2006). 2017;23:47–9.
[5] Hida K, Wada J, Odawara M, et al. Malignant hypertension with a rare complication of pulmonary alveolar hemorrhage. Am J Nephrol. 2000;20:64–7.
[6] Haas AR, Marik PE. Current diagnosis and management of hypertensive emergency. Semin Dial. 2006;19:502–12.
[7] Sato Y, Hara S, Yamada K, et al. A rare case of alveolar haemorrhage due to malignant hypertension. Nephrol Dial Transplant. 2005;20:2289–90.
[8] Aithal S, Marley N, Venkat-Raman G. An unusual non-immunological cause of renal pulmonary syndrome. Clin Nephrol. 2009;72:322–5.
[9] Dalal P, Phadke G, Gill A, et al. A patient with hemoptysis and renal failure. Int J Hypertens. 2011;268370.
[10] Park HS, Hong YA, Chung BH, et al. Malignant hypertension with an unusual presentation mimicking the immune mediated pulmonary renal syndrome. Yonsei Med J. 2012;53:1224–7.